Frontline Golcadomide/R-CHOP Combo Elicits Antitumor Activity in Aggressive B-Cell Lymphoma
Preliminary findings from the phase 1b CC-220-DLBCL-001 trial show that combining golcadomide (0.4 mg) with R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine, prednisone) is well-tolerated and yields high metabolic response rates in previously untreated aggressive B-cell lymphoma patients. The 0.4-mg dose achieved an 88% complete metabolic response rate, with promising 12-month progression-free survival in both overall and high-risk groups. Golcadomide, a first-in-class oral CELMoD agent, demonstrated a toxicity profile similar to R-CHOP and maintained good dose intensity.
Related Clinical Trials
Reference News
Preliminary findings from the phase 1b CC-220-DLBCL-001 trial show that combining golcadomide (0.4 mg) with R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine, prednisone) is well-tolerated and yields high metabolic response rates in previously untreated aggressive B-cell lymphoma patients. The 0.4-mg dose achieved an 88% complete metabolic response rate, with promising 12-month progression-free survival in both overall and high-risk groups. Golcadomide, a first-in-class oral CELMoD agent, demonstrated a toxicity profile similar to R-CHOP and maintained good dose intensity.